Adverse events associated with paediatric intrathecal baclofen in Australia: 5 years of data collection.
adverse event
intrathecal baclofen
paediatric rehabilitation
paediatrics
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
23
02
2020
revised:
09
08
2020
accepted:
14
08
2020
pubmed:
26
9
2020
medline:
15
5
2021
entrez:
25
9
2020
Statut:
ppublish
Résumé
This study aims to examine the adverse event (AE) rate for intrathecal baclofen (ITB) therapy in an Australian paediatric population and to clarify type and frequency of AEs. AE data were extracted from the Australian Paediatric ITB Research Group national database, to include the first 5 years of data collection. Raw data were collated and analysed descriptively. Data were collected for 40 patients. Forty-seven AEs in 23 patients were reported. Ten (25%) patients required surgical intervention related to their AE. Five patients (12.5%) required pump removal. The most frequent ITB-related AEs were catheter dysfunction (24%), drug overdose, withdrawal or sensitivity (19%), seromas and haematomas (15%) and infections (13%). The AE rate for ITB therapy is high and needs to be considered when counselling patients regarding ITB as a therapeutic option.
Substances chimiques
Muscle Relaxants, Central
0
Baclofen
H789N3FKE8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-262Subventions
Organisme : Children's Health Queensland Study, Education and Research Trust (SERTA) grant
Informations de copyright
© 2020 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Hasnat MJ, Rice JE. Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cochrane Database Syst. Rev. 2015; 11: CD004552.
Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. Dev. Med. Child Neurol. 2000; 42: 634-45.
Davidoff RA. Antispasticity drugs: Mechanisms of action. Ann. Neurol. 1985; 17: 107-16.
Ertzgaard P, Campo C, Calabrese A. Efficiency and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen. J. Rehabil. Med. 2017; 49: 193-203.
Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J. Neurosurg. Pediatr. 2014; 13: 301-6.
Borowski A, Littleton AG, Borkhuu B et al. Complications of intrathecal baclofen pump therapy in pediatric patients. J. Pediatr. Orthop. 2010; 30: 76-81.
Watve SV, Sivan M, Raza WA, Jamil FF. Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord 2012; 50: 107-11.
Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome - A life-threatening complication of baclofen pump: A case report. BMC Clin. Pharmacol. 2004; 4: 6.
Liew PY, Stewart K, Khan D, Arnup SJ, Scheinberg A. Intrathecal baclofen therapy in children: An analysis of individualised goals. Dev. Med. Child Neurol. 2018; 60: 367-73.
Ward A, Hayden S, Dexter M, Sheinberg A. Continuous intrathecal baclofen for children with spasticity and/or dystonia: Gaol attainment and complication associated with treatment. J. Paediatr. Child Health 2009; 45: 720-6.
Kraus T, Gegenleitner K, Svehlik M, Novak M, Steinwender G, Singer G. Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. Eur. J. Paediatr. Neurol. 2017; 21: 565-9.
Stewart K, Hutana G, Kentish M. Intrathecal baclofen therapy in paediatrics: A study protocol for an Australian multi-centre, 10 year, prospective audit. BMJ Open 2017; 7: e015863.
Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev. Med. Child Neurol. 1997; 39: 214-23.
Buizer A, Martens BHM, van Ravenhorst CG, Schoonmade LJ, Becher JG, Vermeulen RJ. Effect of continuous intrathecal baclofen therapy in children: A systematic review. Dev. Med. Child Neurol. 2019; 61: 128-34.
Zdolsek H, Olesch C, Antolovich G, Reddihough D. Intrathecal baclofen therapy: Benefits and complications. J. Intellect. Dev. Disabil. 2011; 36: 207-13.
Dastgir A, Ranalli NJ, MacGregor TL, Aldana PR. Baclofen pump catheter leakage after migration of the abdominal catheter in a pediatric patient with spasticity. J. Neurosurg. Pediatr. 2015; 16: 335-9.
Swinney CM, Bau K, Burton KLO, O'Flaherty SJ, Bear NL, Paget SP. Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections. Dev. Med. Child Neurol. 2018; 60: 498-504.
Naidu K, Smith K, Sheedy M, Adair B, Yu X, Graham HK. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev. Med. Child Neurol. 2010; 52: 139-44.